Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of STSA-1002 in Healthy Subjects
NCT05497635Phase 1Completed
- Sponsor
- Staidson Biopharmaceutical
- Start
- Oct 2022
- Primary completion
- Apr 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of STSA-1002 in acute respiratory distress syndrome (ARDS) (3 arms), sponsored by Staidson Biopharmaceutical. Primary endpoints: Incidence of Adverse Events, Clinically Significant Laboratory Abnormalities, Clinically Significant Electrocardiogram, Vital Signs And Physical Examination Abnormalities at Day 56, Maximum plasma concentration at Day 56 and 4 more. Started Oct 2022; status: completed.
02
Drugs
STSA-1002
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT05497635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05497635.